ES2183583T3 - Agente con efecto antidepresivo, que contiene pramipexol y sertralina. - Google Patents

Agente con efecto antidepresivo, que contiene pramipexol y sertralina.

Info

Publication number
ES2183583T3
ES2183583T3 ES99934560T ES99934560T ES2183583T3 ES 2183583 T3 ES2183583 T3 ES 2183583T3 ES 99934560 T ES99934560 T ES 99934560T ES 99934560 T ES99934560 T ES 99934560T ES 2183583 T3 ES2183583 T3 ES 2183583T3
Authority
ES
Spain
Prior art keywords
sertraline
agent
pramipexol
antidepressive effect
antidepressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99934560T
Other languages
English (en)
Inventor
Jerzy Maj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Application granted granted Critical
Publication of ES2183583T3 publication Critical patent/ES2183583T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agente para el tratamiento de depresiones, que contiene 2-amino-4,5,6,7-tetrahidro-6-propilamino- benzotiazol, uno de sus enantiómeros o una de sus sales por adición de ácidos, en combinación con sertralina o una de sus sales farmacológicamente compatibles.
ES99934560T 1998-07-07 1999-07-02 Agente con efecto antidepresivo, que contiene pramipexol y sertralina. Expired - Lifetime ES2183583T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung

Publications (1)

Publication Number Publication Date
ES2183583T3 true ES2183583T3 (es) 2003-03-16

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99934560T Expired - Lifetime ES2183583T3 (es) 1998-07-07 1999-07-02 Agente con efecto antidepresivo, que contiene pramipexol y sertralina.

Country Status (32)

Country Link
US (1) US6255329B1 (es)
EP (1) EP1093369B1 (es)
JP (1) JP2002520273A (es)
KR (1) KR100557692B1 (es)
CN (1) CN1230168C (es)
AR (1) AR019896A1 (es)
AT (1) ATE228365T1 (es)
AU (1) AU762128B2 (es)
BG (1) BG64972B1 (es)
BR (1) BR9911768A (es)
CA (1) CA2336833C (es)
CZ (1) CZ294087B6 (es)
DE (2) DE19830201A1 (es)
DK (1) DK1093369T3 (es)
EA (1) EA003142B1 (es)
EE (1) EE04296B1 (es)
ES (1) ES2183583T3 (es)
HU (1) HUP0103922A3 (es)
ID (1) ID27776A (es)
IL (1) IL140603A0 (es)
MY (1) MY117969A (es)
NO (1) NO20010064L (es)
NZ (1) NZ509729A (es)
PL (1) PL195043B1 (es)
PT (1) PT1093369E (es)
RS (1) RS49795B (es)
SK (1) SK284923B6 (es)
TR (1) TR200100146T2 (es)
TW (1) TW592698B (es)
WO (1) WO2000002542A2 (es)
YU (1) YU401A (es)
ZA (1) ZA200100090B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CN102160865A (zh) 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
JP2012500283A (ja) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
MX2011011579A (es) * 2009-04-30 2012-01-27 Supernus Pharmaceuticals Inc Metodo de tratamiento contra la depresion.
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP4233915A3 (en) 2012-02-08 2023-09-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS67279B1 (sr) 2013-07-12 2025-10-31 Areteia Therapeutics Inc Lečenje povišenih nivoa eozinofila i/ili bazofila
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
AU2018290889B2 (en) * 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
HUP9902160A3 (en) * 1996-03-29 2001-02-28 Pfizer Benzyl(idene)-lactam derivatives, their use as selective (ant)agonists of 5-ht1a-and/or 5-ht1d receptors, pharmaceutical compositions containing these compounds
WO1998024446A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating movement disorders
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
ZA200100090B (en) 2002-04-04
NO20010064D0 (no) 2001-01-05
PT1093369E (pt) 2003-03-31
KR20010079491A (ko) 2001-08-22
WO2000002542A3 (de) 2000-06-22
US6255329B1 (en) 2001-07-03
KR100557692B1 (ko) 2006-03-07
WO2000002542A2 (de) 2000-01-20
RS49795B (sr) 2008-06-05
BG105112A (bg) 2001-10-31
DK1093369T3 (da) 2002-12-16
EE04296B1 (et) 2004-06-15
IL140603A0 (en) 2002-02-10
EE200100014A (et) 2002-06-17
SK284923B6 (sk) 2006-02-02
EP1093369B1 (de) 2002-11-27
EP1093369A2 (de) 2001-04-25
BR9911768A (pt) 2001-04-03
SK112001A3 (en) 2001-10-08
BG64972B1 (bg) 2006-11-30
AU762128B2 (en) 2003-06-19
PL345842A1 (en) 2002-01-14
DE19830201A1 (de) 2000-01-13
ATE228365T1 (de) 2002-12-15
CN1230168C (zh) 2005-12-07
CN1308533A (zh) 2001-08-15
NO20010064L (no) 2001-03-02
MY117969A (en) 2004-08-30
AU5030399A (en) 2000-02-01
EA200100084A1 (ru) 2001-08-27
NZ509729A (en) 2003-06-30
TW592698B (en) 2004-06-21
CA2336833C (en) 2008-09-23
ID27776A (id) 2001-04-26
AR019896A1 (es) 2002-03-20
CZ294087B6 (cs) 2004-10-13
HUP0103922A2 (hu) 2002-03-28
TR200100146T2 (tr) 2001-07-23
PL195043B1 (pl) 2007-08-31
HUP0103922A3 (en) 2002-08-28
CA2336833A1 (en) 2000-01-20
EA003142B1 (ru) 2003-02-27
CZ200177A3 (en) 2001-06-13
DE59903556D1 (de) 2003-01-09
HK1037976A1 (en) 2002-03-01
YU401A (sh) 2003-10-31
JP2002520273A (ja) 2002-07-09

Similar Documents

Publication Publication Date Title
AR019896A1 (es) Agente con efecto antidepresivo
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
AR023529A1 (es) Una composicion champu acondicionadora del cabello y un metodo para acondicionar el cabello
BR0013826A (pt) Formas orais de apresentação
AR064901A2 (es) Una pelicula consumible adaptada para disolverse en la boca de un consumidor
AR010348A1 (es) Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen
ES2100100T3 (es) Composicion para aplicacion topica que contiene una lipasa y un precursor de agente activo.
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
BR0114628A (pt) Membro de retenção em microprojeção para aplicador de impacto
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
DE60144401D1 (de) Aspirin-ausgelöste Lipidmediatoren
UY26850A1 (es) Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida.
AR046970A1 (es) Esteres de fosfato de florfenicol
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
ES2123734T3 (es) Composicion de tincion por oxidacion de fibras queratinicas que comprenden un para-amino-fenol, el 2-metil-5-aminofenol y una para-fenilendiamina y/o una bis-fenilalquilendiamina.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
AR034200A1 (es) Agente para el cuidado de lentes de contacto, su uso, y procedimiento de limpieza
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
BR0312782A (pt) Composição para o tratamento de manchas
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
ES2193065T3 (es) Nueva utilizacion del saredutant.
BR0308170A (pt) Composição para limpeza lìquida aquosa, método para limpeza de um substrato, e, uso de um polioxometalato
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
PY990129A (es) Bromhidrato de eletriptan monohidratado